FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint

This article was originally published here

FKD Therapies Oy (FKD) has led the development and regulatory filing of nadofaragene firadenovec, which has been studied in 33 centers across the U.S. in collaboration with the

The post FerGene’s phase 3 NMIBC study of Nadofaragene Firadenovec meets primary endpoint appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply